Our commitments
- Quality, ethics and transparency
- Put people at the heart of our growth
- Our agility at the service of a dynamic industry
Therapeutic areas
Key figures
20
add-on since 2015>90M
euros turnover18
brands and 26 products80+
countries covered40+
collaborators between France, Ireland and US
LXO Group publishes its latest ESG report
LXO Group is proud to announce the publication of its latest ESG report. The report details the company's efforts and achievements over the past year in terms of sustainability, ethics and social commitment.
Read more
LXO Group announces the acquisition of prescription drug Nimotop® from Bayer
Press Release, november 06th, 2023 - Laboratoire X.O ("LXO"), is pleased to announce the acquisition of prescription drug Nimodipine under the brand name Nimotop® from Bayer, for several markets across different regions excluding Mainland China.
Read more
Laboratoire XO is moving!
To support its growth, Laboratoire XO is moving to new premises and reaching for the sky!
Read moreWe are delighted to announce the acquisition of prescription drug Nimotop® from Bayer.
This acquisition is a major milestone in LXO's history. We believe that this will provide a fruitful ground for further accelerated growth through both organic and external opportunities. We are very proud to take under our responsibility life-saving drugs such as Nimotop® and we are committed to maintain and develop the access to this treatment in more than 45 countries. This acquisition strengthens our international footprint and offers exciting new opportunities for our future. We are thrilled with this development and determined to make the most of this opportunity for the patients, our employees and our shareholders.